Payment overview · 2025
General Payments
$534.99
30 reported records · 15 companies
Healthcare provider profile · identity verified
Dwight Thomas Curtis, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · RAYNE, LA · NPI 1902806128
Verified facts
What the public records show
CMS Open Payments records show Dwight Thomas Curtis, M.D. received $534.99 in general payments during 2025 across 30 reported records.
ABBVIE INC. accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 299 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $134.75 | 25.2% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.73 | 10.4% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $37.68 | 7.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.54 | 6.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.61 | 6.3% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $32.76 | 6.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.02 | 6.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.82 | 5.8% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $26.14 | 4.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.52 | 4.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.98 | 4.1% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $18.96 | 3.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.21 | 3.4% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.08 | 3.4% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $16.19 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $534.99 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $84.25 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.73 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $52.35 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $37.68 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.87 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $33.61 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $32.76 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.82 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $26.14 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.21 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| DUROLANE Normalized: durolane |
Device | Bioventus LLC | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 183 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 146 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
183 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
221 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
146 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
299 | 30 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
81 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1033 | 196 |
| Amlodipine Besylate | Amlodipine Besylate | 831 | 143 |
| Metformin Hcl | Metformin Hcl | 701 | 135 |
| Gabapentin | Gabapentin | 611 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 574 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 483 | 79 |
| Lisinopril | Lisinopril | 389 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 361 | 78 |
| Eliquis | Apixaban | 299 | 30 |
| Losartan Potassium | Losartan Potassium | 290 | 50 |
| Furosemide | Furosemide | 286 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 282 | 48 |
| Carvedilol | Carvedilol | 272 | 37 |
| Trazodone Hcl | Trazodone Hcl | 267 | 49 |
| Potassium Chloride | Potassium Chloride | 262 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 261 | 46 |
| Donepezil Hcl | Donepezil Hcl | 232 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 228 | 59 |
| Ezetimibe | Ezetimibe | 227 | 37 |
| Mirtazapine | Mirtazapine | 221 | 39 |
| Trulicity | Dulaglutide | 221 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 207 | 38 |
| Alendronate Sodium | Alendronate Sodium | 185 | 40 |
| Jardiance | Empagliflozin | 183 | 28 |
| Omeprazole | Omeprazole | 180 | 33 |
| Meloxicam | Meloxicam | 164 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 161 | 37 |
| Alprazolam | Alprazolam | 150 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 146 | 36 |
| Ozempic | Semaglutide | 146 | 26 |
| Farxiga | Dapagliflozin Propanediol | 145 | 15 |
| Tramadol Hcl | Tramadol Hcl | 145 | 27 |
| Allopurinol | Allopurinol | 144 | 31 |
| Sertraline Hcl | Sertraline Hcl | 143 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 141 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 140 | 29 |
| Xarelto | Rivaroxaban | 137 | 12 |
| Warfarin Sodium | Warfarin Sodium | 132 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 119 | 19 |
| Glimepiride | Glimepiride | 114 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 19 |
| Glipizide | Glipizide | 104 | 21 |
| Spironolactone | Spironolactone | 100 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 99 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 22 |
| Benazepril Hcl | Benazepril Hcl | 96 | 21 |
| Buspirone Hcl | Buspirone Hcl | 95 | 20 |
| Metformin Hcl Er | Metformin Hcl | 87 | 19 |
| Simvastatin | Simvastatin | 87 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 85 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 21 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 81 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 77 | 14 |
| Finasteride | Finasteride | 77 | 13 |
| Clonazepam | Clonazepam | 75 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 11 |
| Montelukast Sodium | Montelukast Sodium | 71 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 70 | suppressed |
| Levetiracetam | Levetiracetam | 69 | 12 |
| Memantine Hcl | Memantine Hcl | 69 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 12 |
| Famotidine | Famotidine | 64 | 16 |
| Irbesartan | Irbesartan | 64 | suppressed |
| Torsemide | Torsemide | 64 | suppressed |
| Prednisone | Prednisone | 63 | 36 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 42 |
| Mounjaro | Tirzepatide | 61 | suppressed |
| Risperidone | Risperidone | 60 | suppressed |
| Linzess | Linaclotide | 59 | suppressed |
| Azithromycin | Azithromycin | 58 | 48 |
| Valsartan | Valsartan | 56 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 55 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 51 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 12 |
| Baclofen | Baclofen | 49 | suppressed |
| Novolin R | Insulin Regular, Human | 48 | suppressed |
| Fenofibrate | Fenofibrate | 47 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | suppressed |
| Glipizide Er | Glipizide | 46 | 12 |
| Primidone | Primidone | 46 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 42 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | suppressed |
| Pregabalin | Pregabalin | 41 | suppressed |
| Atenolol | Atenolol | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 27 |
| Cephalexin | Cephalexin | 38 | 27 |
| Novolog Flexpen | Insulin Aspart | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Naproxen | Naproxen | 36 | 16 |
| Valacyclovir | Valacyclovir Hcl | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 23 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Cefdinir | Cefdinir | 32 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 26 |
| Venlafaxine Hcl | Venlafaxine Hcl | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 19 |
| Acetazolamide | Acetazolamide | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 15 |
| Olanzapine | Olanzapine | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 24 | 17 |
| Lorazepam | Lorazepam | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Novolog | Insulin Aspart | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 22 |
| Ursodiol | Ursodiol | 23 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 22 | suppressed |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Restasis | Cyclosporine | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 11 |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Cyclosporine | Cyclosporine | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 18 | 11 |
| Estradiol | Estradiol | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Cholestyramine Light | Cholestyramine | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | 11 |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Propylthiouracil | Propylthiouracil | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Clobazam | Clobazam | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $534.99 · 30 records | ABBVIE INC. | ABRYSVO, Azstarys, COMIRNATY, Cologuard Collection Kit, DUROLANE, Dexcom G6 Transmitter, IBSRELA, JARDIANCE, MOUNJARO, NEXLETOL, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, REXULTI, TRUMENBA, TZIELD, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error